Company Overview of U.S. Army Medical Research Institute of Infectious Diseases
U.S. Army Medical Research Institute of Infectious Diseases provides laboratory research and development services for medical biological defense catering to military and government sectors. It researches, develops, tests, and evaluates vaccines, drugs, and diagnostic solutions to protect military personnel and civilians from infectious diseases and biological threats. It also offers information to protect people from biological threats such as anthrax, botulism, plague, Ebola, Marburg hemorrhagic fevers, hantavirus, ricin toxin, and staphylococcal enterotoxin B. The company also develops diagnostic assays for medical identification to protect the war fighter against biological threats; and d...
1425 Porter Street
Frederick, MD 21702-5011
Founded in 1969
Key Executives for U.S. Army Medical Research Institute of Infectious Diseases
U.S. Army Medical Research Institute of Infectious Diseases does not have any Key Executives recorded.
U.S. Army Medical Research Institute of Infectious Diseases Key Developments
Paratek Pharmaceuticals, Inc. and U.S. Army Medical Research Institute of Infectious Diseases Enter Research Agreement to Study Omadacycline against Biodefense Pathogens
Oct 11 16
Paratek Pharmaceuticals, Inc. announced that it has entered into a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance. These studies are designed to confirm humanized dosing regimens of omadacycline in order to study the efficacy of omadacycline against biodefense pathogens, including Yersinia pestis (plague) and Bacillus anthracis (anthrax). Funding support for the trial has been made available through the Defense Threat Reduction Agency (DTRA)/Joint Science and Technology Office (JSTO) and Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD)/Joint Project Manager Medical Countermeasure Systems (JPM-MCS)/BioDefense Therapuetics (BDTX). Under the terms of the CRADA, Paratek will provide omadacycline and technical expertise to support USAMRIID’s conduct of the pre-clinical pharmacokinetic studies and efficacy studies of omadacycline against a variety of biodefense pathogens. Data generated from these studies may support further development, which could ultimately lead to the approval of omadacycline in the treatment of these important biodefense pathogens.
Yisheng Biopharma and United States Army Medical Research Institute of Infectious Diseases Announce Collaboration on New Vaccine Against Ebola Virus
Dec 14 15
Yisheng Biopharma Co. Ltd. announced that Yisheng US Biopharma Inc., its wholly owned research subsidiary, has entered into a collaboration with the United States Army Medical Research Institute of Infectious Diseases ("USAMRIID") to develop a new vaccine against the Ebola virus using a novel double-stranded RNA-based Toll-Like Receptor 3 (TLR3) agonist adjuvant technology. The cooperative research partnership represents a new opportunity for both organizations to develop effective and safe vaccine products against Ebola or other viruses. Under the terms of the agreement, the scientists at USAMRIID will evaluate the potential of PIKA adjuvant for Ebola vaccine or other vaccine candidates. The PIKA adjuvant is a proprietary technology developed by Yisheng Biopharma, named as part of "National Key Medicine Innovation" in 2013 by the National Ministry of Science and Technology of China.
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
Jun 3 15
Arno Therapeutics, Inc. announced it has entered into a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the anti-viral activity of AR-12 and various analogues against Ebola and other viruses of biodefense interest. AR-12 is an orally-available small molecule. Data reported previously demonstrate that the AR-12 mechanism of action may include induction of host cell autophagy and inhibition of fungal acetyl coenzyme A synthetase. The precise antiviral mechanism of action of AR-12 continues to be evaluated but an established body of evidence demonstrates that AR-12 is an inducer of host effector cell autophagy. AR-12 is known to inhibit, or down regulate, GRP78 (also known as BiP, HSPA5) the master regulator of the unfolded protein response. The down regulation of GRP78 results in the up-regulation of PERK which induces the formation of autophagosomes and, subsequently, host cell autophagy. AR-12 also down regulates the chaperone proteins HSP70 and HSP90. Previously, AR-12 has completed Phase 1 clinical trials in patients with cancer. Additional pre-clinical research indicates that AR-12 may have potential as an antimicrobial agent in various infectious diseases. AR-12 has been granted two orphan drug designations in Europe for the treatment of cryptococcosis and tularaemia. In addition, Arno also has the rights to a broad portfolio of compounds in the "AR-12 series" which have been demonstrated to have broad spectrum antimicrobial activity.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|